Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer

Clinical Cancer Research

Volumn 7, Issue 7, 2001, Pages 1912-1922

  Levitt, Nicola C ^a   Eskens, Ferry A L M ^b   O'Byrne, Ken J ^c   Propper, David J ^a   Denis, Louis J ^b   Owen, Samantha J ^d   Choi, Les ^d   Foekens, John A ^b   Wilner, Sue ^a   Wood, Jeanette M ^d   Nakajima, Motowo ^d   Talbot, Denis C ^a   Steward, William P ^c   Harris, Adrian L ^a   Verweij, Jaap ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BIOCHEMICAL MARKER; CATHEPSIN B; CATHEPSIN H; CGS 27023A; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; MMI 270; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER STAGING; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; OSTEOLYSIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOLID TUMOR; TUMOR REGRESSION;

ADMINISTRATION, ORAL; ADULT; AGED; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXANTHEMA; FEMALE; HUMANS; HYDROXAMIC ACIDS; MALE; METABOLIC CLEARANCE RATE; METALLOENDOPEPTIDASES; MIDDLE AGED; MUSCULOSKELETAL DISEASES; NAUSEA; NEOPLASMS; PROTEASE INHIBITORS; PYRAZINES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0034772722     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Matrix metalloproteinases and tumor invasion: From correlation and causality to the clinic
2. Matrix metalloproteinase inhibitors
3. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity
4. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions
5. Matrix metalloproteinases: Biologic activity and clinical implications
6. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-α in a model of herniated disc resorption
7. Matrix metalloproteinase-3-dependent generation of a macrophage chemoattractant in a model of herniated disc resorption
8. Metalloproteinases and cancer invasion
9. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas
10. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma
11. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis
12. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer
13. Activity of type IV collagenases in benign and malignant breast disease
14. Matrix metalloproteinases in cancer: Prognostic markers and targets for therapy
15. CGS 27023A, a potent and orally active matrix metalloprotease inhibitor with antitumor activity
16. A one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases-2 using monoclonal antibodies
17. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies
18. A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies
19. Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases. An application for rheumatoid arthritis serum and plasma
20. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 8 (neutrophil collagenase) using monoclonal antibodies
21. Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis
22. Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients
23. The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients
24. New Phase I trial methodology
25. Anticancer agents targeting signaling molecules and cancer cell environment: Challenges for drug development?
26. Matrix metalloproteinase inhibitors: Present achievements and future prospects
27. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites
28. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions
29. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer
30. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites
31. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer term studies
32. Phase I study of BAY 12-9566: A matrix metalloproteinase inhibitor
33. Phase I study of the metalloproteinase inhibitor Bayer 12-9566
34. Phase I and pharmacokinetic study of the matrix metalloproteinase inhibitor, BAY 12-9566
35. Phase I study of the metalloproteinase inhibitor Bayer 12-9566 in patients with advanced cancer
36. Preclinical and clinical studies of MMP inhibitors in cancer
37. Processing of tumour necrosis factor-α precursor by metalloproteinases
38. Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase metal] inhibitor
39. Plasma assay of matrix metalloproteinases (MMPs) and MMP-inhibitor complexes in cancer. Potential use in predicting metastasis and monitoring treatment
40. Type IV collagenase/gelatinase (MMP-2) is not increased in plasma of patients with cancer
41. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family
42. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase
43. Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases
44. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression
45. Heparin affinity: Purification of a tumor-derived capillary endothelial cell growth factor
46. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients
47. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer
48. Neoangiogenesis and p53 protein in lung cancer: Their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression
49. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas
50. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers
51. Expression of basic fibroblast growth factor in primary human renal tumors: Correlation with poor survival
52. The urokinase receptor: Involvement in cell surface proteolysis and cancer invasion
53. Cell adhesion: A new target for therapy
54. Are angiostatin and endostatin cures for cancer